Advertisement

Drugs

, Volume 79, Issue 14, pp 1591–1598 | Cite as

Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer

  • Zaina T. Al-SalamaEmail author
Adis Drug Evaluation

Abstract

Apalutamide (marketed as Erleada®) is an oral non-steroidal next-generation selective inhibitor of the androgen receptor (AR), and is approved in several countries, including the USA and those of the EU, for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). In men with nmCRPC who were receiving androgen-deprivation therapy (ADT) and had a high risk of metastases in SPARTAN, apalutamide significantly prolonged metastasis-free survival (MFS) compared with placebo, with consistent benefits demonstrated across subgroups. The addition of apalutamide to ongoing ADT significantly prolonged time to metastasis and progression-free survival (PFS) compared with placebo, and maintained health-related quality of life (HR-QOL). Apalutamide was generally well tolerated in SPARTAN, with fatigue being the most frequently reported adverse event. Given the available evidence, apalutamide with ongoing ADT represents an emerging treatment option for patients with nmCRPC who are at high risk of developing metastatic disease.

Notes

Acknowledgements

During the peer review process, the manufacturer of apalutamide was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Zaina T. Al-Salama is a salaried employee of Adis International Ltd/Springer Nature is responsible for the article content and declares no relevant conflicts of interest

References

  1. 1.
    El-Amm J, Aragon-Ching JB. The current landscape of treatment in non-metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 2019.  https://doi.org/10.1177/1179554919833927.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Esther J, Maughan BL, Anderson N, et al. Management of nonmetastatic castration-resistant prostate cancer: recent advances and future direction. Curr Treat Options Oncol. 2019.  https://doi.org/10.1007/s11864-019-0611-z.CrossRefPubMedGoogle Scholar
  3. 3.
    Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–503.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Janssen Pharmaceutical Companies. ErleadaTM (apalutamide): US prescribing information. 2018. http://www.fda.gov/. Accessed 16 Aug 2019.
  5. 5.
    European Medicines Agency. Erleada (apalutamide): EU summary of product characteristics. 2019. http://www.ema.europa.eu/. Accessed 16 Aug 2019.
  6. 6.
    Koukourakis MI, Kakouratos C, Kalamida D, et al. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines. Anticancer Drugs. 2018;29(4):323–33.CrossRefPubMedGoogle Scholar
  7. 7.
    Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3(9):1020–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Rathkopf DE, Smith MR, Ryan CJ, et al. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol. 2017;28(9):2264–71.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013.  https://doi.org/10.7554/eLife.00499.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Korpal M, Korn JM, Gao X, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013;3(9):1030–43.CrossRefPubMedGoogle Scholar
  11. 11.
    Smith MR, Thomas S, Chowdhury S, et al. Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study [abstract no. 2605]. Cancer Res. 2018;78(13 Suppl).Google Scholar
  12. 12.
    Espaillat MP, Rajpurohit Y, Gormley M, et al. Digital droplet PCR (ddPCR)-based detection of androgen receptor splice variant 7 (AR-v7) in non-metastatic castration resistant prostate [abstract no. 1335]. In: AACR Annual Meeting 2019 Proceedings. 2019.Google Scholar
  13. 13.
    Feng FY, Thomas S, Gormley M, et al. Identifying molecular determinants of response to apalutamide (APA) in patients (PTS) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial [abstract no. 42]. J Clin Oncol. 2019;37(7 Suppl).Google Scholar
  14. 14.
    Belderbos BPSI, de Wit R, Chien C, et al. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2018;82(3):457–68.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525–30.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–18.CrossRefPubMedGoogle Scholar
  17. 17.
    Smith MR, Antonarakis ES, Ryan CJ, et al. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol. 2016;70(6):963–70.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Janssen Research & Development. A multicenter, randomized, double-blind, placebo-controlled, phase III study of ARN509 in men with non-metastatic (M0) castration-resistant prostate cancer—selective prostate AR targeting with ARN-509 (SPARTAN): clinical study report. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/rev_210951_arn-509-003_CSR_Redacted.pdf. Accessed 22 Aug 2019.
  19. 19.
    Mainwaring P, Small E, Uemura H, et al. Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation [abstract no. 2130]. Ann Oncol. 2018;29(Suppl 9).Google Scholar
  20. 20.
    Hadaschik BA, Saad F, Graff JN, et al. Efficacy and safety of apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients (pts) with or without prior radical prostatectomy (RP) and/or external radiotherapy (XRT): post hoc analysis of SPARTAN [abstract no. MP34-19]. J Urol. 2019;201(Suppl 4):e502–3.Google Scholar
  21. 21.
    Saad F, Thomas S, Feng FY, et al. Response to apalutamide (APA) among patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN by Decipher Genomic Classifier (GC) score [abstract no. PD11-03]. J Urol. 2019;201(4 Suppl):e216.Google Scholar
  22. 22.
    Small EJ, Saad F, Chowdhury S, et al. Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM) [abstract no. 5023]. J Clin Oncol. 2019;37(Suppl).Google Scholar
  23. 23.
    Graff J, Saad F, Hadaschik BA, et al. Metastasis-free survival (MFS) in nonmetastatic castration-resistant prostate cancer (NMCRPC) patients (pts) with prostate-specific antigen (PSA) decline to < 0.2 ng/ml following apalutamide (APA) treatment: post hoc results from the phase 3 SPARTAN study [abstract no. MP34-20]. J Urol. 2019;201(Suppl 4):e503.Google Scholar
  24. 24.
    Small EJ, Saad F, Rathkopf DE, et al. Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): an analysis from the phase 3 SPARTAN trial [abstract no. 5034]. J Clin Oncol. 2018;36(15 Suppl).Google Scholar
  25. 25.
    Smith MR, Mehra M, Nair S, et al. Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC) [abstract no. 5032]. J Clin Oncol. 2018;36(15 Suppl).Google Scholar
  26. 26.
    Small EJ, Saad F, Chowdhury S, et al. Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) [abstract no. 144]. J Clin Oncol. 2019;37(7 Suppl).Google Scholar
  27. 27.
    Saad F, Cella D, Basch E, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(10):1404–16.CrossRefPubMedGoogle Scholar
  28. 28.
    Data on file, Janssen Pharmaceutical Companies, 2019.Google Scholar
  29. 29.
    Pollock YY, Smith MR, Saad F, et al. Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). [abstract no. 5025]. J Clin Oncol. 2019;37(Suppl).Google Scholar
  30. 30.
    European Association of Urology. EAU oncology guidelines: prostate cancer. 2019. https://uroweb.org/guideline/prostate-cancer/#1. Accessed 23 Jul 2019.
  31. 31.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. 2019. http://www.nccn.org/. Accessed 16 Aug 2019.
  32. 32.
    Chowdhury S, Oudard S, Hadaschik BA, et al. Matching-adjusted indirect comparison of the efficacy of apalutamide and enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer [abstract no. PCN37]. Value Health. 2018;21 (Suppl 3):S20–1.Google Scholar
  33. 33.
    Wallis CJD, Chandrasekar T, Goldberg H, et al. Advanced androgen blockage in nonmetastatic castration-resistant prostate cancer: an indirect comparison of apalutamide and enzalutamide. Eur Urol Oncol. 2018;1(3):238–41.CrossRefPubMedGoogle Scholar
  34. 34.
    Riaz IB, Bhattacharjee S, Malik S, et al. Apalutamide (APA) or enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (CRPC): a systematic review and network meta-analysis of randomized clinical trials (RCTs) [abstract no. 263]. J Clin Oncol. 2019;37(7 Suppl).Google Scholar
  35. 35.
    Zhou Z, Hu X. Cost-effectiveness analysis of apalutamide for treatment in non-metastasis castration-resistant prostate cancer [abstract no. PCN153]. Value Health. 2018;21 (Suppl 3):S40–1.Google Scholar
  36. 36.
    Beaver JA, Kluetz PG, Pazdur R. Metastasis-free survival: a new end point in prostate cancer trials. N Engl J Med. 2018;378(26):2458–60.CrossRefPubMedGoogle Scholar
  37. 37.
    Chandler R, De Bono J. Second-generation antiandrogens in nonmetastatic CRPC. Nat Rev Urol. 2018;15(6):342–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Gagnon R, Ali-Mohamed NS, Batuyong E, et al. Metastasis-free survival as a predictor of overall survival in non-metastatic castration-resistant prostate cancer [abstract no. 201]. J Clin Oncol. 2019;37(7 Suppl).Google Scholar
  39. 39.
    Schultz NM, Sugarman R, Ramaswamy K, et al. Clinical benefits and risk of enzalutamide and apalutamide: number needed to treat and number needed to harm analysis for patients with non-metastatic castration-resistant prostate cancer [abstract no. MP34-18]. J Urol. 2019;201(Suppl 4):e502.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations